Paterson, R.W., Brown, R.L., Benjamin, L., Nortley, R., Wiethoff, S., Bharucha, T., Jayaseelan, D.L., Kumar, G., Raftopoulos, R.E., Zambreanu, L., Vivekanandam, V., et al. (2020) The Emerging Spectrum of COVID-19 Neurology: Clinical, Radiological and Laboratory Findings. Brain, 143, 3104-3120.
https://doi.org/10.1093/brain/awaa240

has been cited by the following article:

• TITLE: A Case of COVID-19 Related Myasthenic Crisis: Lessons Learned

  AUTHORS: Folajimi M. Otubogun, Adegoke M. Fatunwase, Olaniyi M. Fowosola, Khadijat M. Alli, Ojuolape O. Okedara, Bamidele S. Osalusi

  KEYWORDS: Myasthenia Gravis, COVID-19, SARS-COV-2, Low Resource Settings

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.14 No.8, August 4, 2023

  ABSTRACT: Background: COVID-19 was initially described to affect the respiratory system, it is now known to affect other systems and present in a myriad of ways. This has often proved to be a diagnostic and therapeutic challenge to clinicians and stretched healthcare resources, sometimes with poor outcomes. We report on an atypical presentation of SARS-CoV-2 infection as an acute exacerbation of myasthenia gravis in a low resource setting. Case Presentation: A middle aged male with myasthenia gravis presented with a three weeks’ history of worsening generalized weakness and three days’ history of new-onset dysphagia with no history of fever and cough. After a few days of apparent improvement, the patient developed progressive respiratory distress. Further evaluation confirmed bilateral pneumonia and COVID-19. Conclusion: There is a need for clinicians and health service providers to have a low threshold for suspicion and testing for COVID-19 in patients with pre-existing medical conditions and immunomodulatory therapy such as Myasthenia gravis.